On October 17, Hyperliquid Strategies Inc fell 8.21% in Regular Trading, trading at 9.03 USD/share, with Turnover of 81.24 million USD.
Within the Biotechnology sector where Hyperliquid Strategies Inc belongs, peer moves were mixed. Moderna, Inc. fell 10.91%, AbbVie rose 0.86%, Amgen fell 0.31%, Gilead Sciences fell 0.85%, and Vertex Pharmaceuticals fell 1.97%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments